# Phase III Trial to Assess the Safety and Efficacy of TK-254RX in Patients With Contusions

> **NCT06871046** · PHASE3 · COMPLETED · sponsor: **Teikoku Seiyaku Co., Ltd.** · enrollment: 221 (actual)

## Conditions studied

- Contusions

## Interventions

- **DRUG:** Esflurbiprofen Topical System (EFTS)

## Key facts

- **NCT ID:** NCT06871046
- **Lead sponsor:** Teikoku Seiyaku Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-20
- **Primary completion:** 2025-09-22
- **Final completion:** 2025-10-01
- **Target enrollment:** 221 (ACTUAL)
- **Last updated:** 2025-10-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06871046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06871046, "Phase III Trial to Assess the Safety and Efficacy of TK-254RX in Patients With Contusions". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06871046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*